

Kestrel Nutrition Kft.

FIVE-YEAR OPERATING MODEL

Integrated profit & loss, balance sheet and cash flow · FY2024A – FY2030E

Purpose	Budget, bank refinancing and scenario testing
Structure	Three fully linked statements with supporting schedules
Scenarios	Base, upside and downside — one switch drives the whole model
Currency	EUR, presented in thousands
Prepared by	Tarlan Charkasov, ACCA
Version	1.0 · July 2026

HOW THIS MODEL IS BUILT

Assumptions	Every input in the model sits here, in blue. Nothing is hardcoded inside a statement.
Schedules	Fixed assets, right-of-use assets, bank debt, leases, working capital, tax and equity roll-forwards.
P&L	Two years of actuals and five forecast years, driven entirely by the assumptions.
Balance Sheet	Every balance flows from a schedule. The check row is nil in all seven years.
Cash Flow	Indirect method, derived from the statements — no plugs anywhere.
Outputs	Headline summary, credit metrics, charts and integrity checks.

MODELLING CONVENTIONS

Blue text	Hardcoded input — safe to change
Black text	Formula — do not overwrite
Costs	Shown as negative figures throughout
Interest	Charged on opening balances, so the model contains no circular references
Cash	The balancing item; there is no revolver and no plug line

SAMPLE DOCUMENT. Kestrel Nutrition Kft. is a fictional company and every figure in this model is illustrative. It is published as a work sample to show model architecture and financial logic — no client data appears anywhere in this file.

Kestrel Nutrition Kft. — Output summary

Headline forecast, credit metrics and integrity checks | EUR '000

Scenario in force

BASE CASE


Change the switch on the Assumptions tab (cell C5) to reflex the whole model.

EUR '000 unless stated	FY2024A	FY2025A	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Trading							
Net revenue	8,420	9,610	10,763	11,840	12,905	13,937	14,913
Revenue growth		14.1%	12.0%	10.0%	9.0%	8.0%	7.0%
Gross margin	45.0%	46.0%	45.8%	46.3%	46.8%	47.0%	47.2%
EBITDA	519	750	792	1,006	1,237	1,428	1,616
EBITDA margin	6.2%	7.8%	7.4%	8.5%	9.6%	10.2%	10.8%
EBIT	304	512	549	751	972	1,151	1,327
Profit for the year	184	352	364	546	746	911	1,075
Cash & capital							
Cash generated from operations		773	733	941	1,157	1,370	1,538
Capital expenditure		(286)	(301)	(308)	(323)	(334)	(358)
Free cash flow before financing		340	170	437	619	804	936
Closing cash	630	615	427	504	536	700	944
Credit metrics							
Net debt		1,565	1,395	958	562	32	(582)
Net debt / EBITDA		2.09x	1.76x	0.95x	0.45x	0.02x	-0.36x
EBITDA interest cover		8.52x	6.76x	10.28x	15.79x	24.33x	41.58x
Return on capital employed		13.4%	13.7%	18.3%	22.9%	26.5%	29.6%
Integrity checks							
Balance sheet balances	OK	OK	OK	OK	OK	OK	OK
Cash flow ties to the balance sheet		OK	OK	OK	OK	OK	OK
Cash above the EUR 250k minimum	OK	OK	OK	OK	OK	OK	OK
Leverage inside the 2.25x covenant		OK	OK	OK	OK	OK	OK


Net revenue and EBITDA margin

Net debt and leverage

Net revenue and EBITDA margin



Net debt and leverage



Kestrel Nutrition Kft. — Model assumptions

Blue cells are inputs. Change the scenario switch below to flex the whole model.

SCENARIO SWITCH1Base case

1 = Base case 2 = Upside 3 = Downside

EUR '000 unless stated	FY2024A	FY2025A	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
------------------------	---------	---------	---------	---------	---------	---------	---------

SCENARIO TABLE — the three levers that drive the case

Net revenue growth

Base	12.0%	10.0%	9.0%	8.0%	7.0%
Upside	16.0%	14.0%	12.0%	10.0%	9.0%
Downside	7.0%	5.0%	4.0%	4.0%	3.0%

Gross margin

Base	45.8%	46.3%	46.8%	47.0%	47.2%
Upside	46.5%	47.2%	47.8%	48.0%	48.2%
Downside	44.5%	44.5%	44.8%	45.0%	45.0%

Sales & marketing (% of net revenue)

Base	14.0%	13.9%	13.8%	13.7%	13.6%
Upside	14.8%	14.6%	14.4%	14.2%	14.0%
Downside	13.2%	13.0%	12.9%	12.8%	12.7%

ACTIVE DRIVERS — selected by the scenario switch

Net revenue growth	12.0%	10.0%	9.0%	8.0%	7.0%
Gross margin	45.8%	46.3%	46.8%	47.0%	47.2%
Sales & marketing (% of net revenue)	14.0%	13.9%	13.8%	13.7%	13.6%

Driven by the switch in cell C5

OPERATING COSTS

Distribution & logistics (% of net revenue)	6.2%	6.1%	6.0%	6.0%	5.9%
Personnel cost growth	9.0%	8.0%	7.0%	6.0%	6.0%
Other operating expense growth	5.0%	5.0%	5.0%	5.0%	5.0%

Headcount plus CEE wage inflation

CAPITAL EXPENDITURE & DEPRECIATION

Capex (% of net revenue)	2.8%	2.6%	2.5%	2.4%	2.4%
Depreciation rate (% of opening PP&E and intangibles)	10.5%	10.5%	10.5%	10.5%	10.5%
Right-of-use asset amortisation	52	52	52	52	52

Straight line over the remaining property lease term

WORKING CAPITAL — 365 day basis

Days sales outstanding	80.0	77.0	75.0	73.0	72.0
Days inventory outstanding	126.0	122.0	118.0	115.0	112.0
Days payables outstanding	148.0	145.0	142.0	140.0	138.0
Other receivables (% of net revenue)	3.0%	3.0%	3.0%	3.0%	3.0%
Accruals (% of cash operating costs)	16.9%	16.9%	16.9%	16.9%	16.9%

Collection improvement plan; FY2025 actual was 84 days

Supplier terms are stretched; a negotiated unwind is assumed

FINANCING & TAX

Bank loan repayment	300	300	300	300	300
Interest rate on bank debt	5.5%	5.5%	5.5%	5.5%	5.5%
Interest rate on lease liabilities	5.0%	5.0%	5.0%	5.0%	5.0%
Annual lease payment	84	84	84	84	84
Interest earned on cash	1.0%	1.0%	1.0%	1.0%	1.0%
Effective tax rate	17.0%	17.0%	17.0%	17.0%	17.0%
Tax charge unpaid at year end	25.0%	25.0%	25.0%	25.0%	25.0%
Dividend payout (% of net profit)	-	-	30.0%	30.0%	30.0%

Contractual amortisation

Facility repriced on refinancing; the legacy blended rate was lower

Final quarter instalment settled after the year end

No distribution until leverage is below 1.0x

Kestrel Nutrition Kft. — Profit & loss account

Two years of actuals and a five year forecast | EUR '000

EUR '000	FY2024A	FY2025A	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Net revenue	8,420	9,610	10,763	11,840	12,905	13,937	14,913
Growth		14.1%	12.0%	10.0%	9.0%	8.0%	7.0%
Gross profit	3,789	4,420	4,930	5,482	6,040	6,551	7,039
Cost of goods sold	(4,631)	(5,190)	(5,834)	(6,358)	(6,866)	(7,387)	(7,874)
Gross margin	45.0%	46.0%	45.8%	46.3%	46.8%	47.0%	47.2%
Distribution & logistics	(545)	(605)	(667)	(722)	(774)	(836)	(880)
Sales & marketing	(1,090)	(1,250)	(1,507)	(1,646)	(1,781)	(1,909)	(2,028)
Personnel costs	(1,285)	(1,430)	(1,559)	(1,683)	(1,801)	(1,909)	(2,024)
Other operating expenses	(350)	(385)	(404)	(424)	(446)	(468)	(491)
Total cash operating costs	(3,270)	(3,670)	(4,137)	(4,476)	(4,802)	(5,123)	(5,423)
EBITDA	519	750	792	1,006	1,237	1,428	1,616
EBITDA margin	6.2%	7.8%	7.4%	8.5%	9.6%	10.2%	10.8%
Depreciation & amortisation	(215)	(238)	(243)	(255)	(266)	(277)	(289)
EBIT	304	512	549	751	972	1,151	1,327
Interest on bank debt	(63)	(59)	(91)	(74)	(58)	(41)	(25)
Interest on lease liabilities	(25)	(29)	(27)	(24)	(21)	(17)	(14)
Interest income on cash	6	-	6	4	5	5	7
Net finance costs	(82)	(88)	(111)	(94)	(73)	(53)	(32)
Profit before tax	222	424	438	658	898	1,097	1,295
Income tax	(38)	(72)	(74)	(112)	(153)	(187)	(220)
Profit for the year	184	352	364	546	746	911	1,075
Net margin	2.2%	3.7%	3.4%	4.6%	5.8%	6.5%	7.2%

Kestrel Nutrition Kft. — Balance sheet

EUR '000 | Forecast balances are driven by the schedules

EUR '000	FY2024A	FY2025A	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Non-current assets							
Property, plant, equipment & intangibles	1,720	1,820	1,930	2,035	2,144	2,254	2,375
Right-of-use assets	572	520	468	416	364	312	260
Deferred tax assets	85	85	85	85	85	85	85
Total non-current assets	2,377	2,425	2,483	2,536	2,593	2,651	2,720
Current assets							
Inventory	1,720	1,845	2,014	2,125	2,220	2,327	2,416
Trade receivables	2,010	2,210	2,359	2,498	2,652	2,787	2,942
Other receivables & prepayments	255	285	323	355	387	418	447
Cash & cash equivalents	630	615	427	504	536	700	944
Total current assets	4,615	4,955	5,123	5,482	5,795	6,233	6,750
TOTAL ASSETS	6,992	7,380	7,606	8,019	8,388	8,884	9,469
Equity							
Share capital	500	500	500	500	500	500	500
Retained earnings	1,390	1,742	2,106	2,652	3,174	3,811	4,564
Total equity	1,890	2,242	2,606	3,152	3,674	4,311	5,064
Non-current liabilities							
Bank loan	1,650	1,350	1,050	750	450	150	-
Lease liabilities	445	385	412	349	282	212	139
Provisions	95	95	95	95	95	95	95
Total non-current liabilities	2,190	1,830	1,557	1,194	827	457	234
Current liabilities							
Trade payables	1,845	2,148	2,365	2,526	2,671	2,833	2,977
Accruals & other payables	545	620	699	756	812	866	917
Bank loan — current portion	300	300	300	300	300	300	150
Lease liabilities — current	140	145	60	63	67	70	73
Income tax payable	82	95	19	28	38	47	55
Total current liabilities	2,912	3,308	3,444	3,673	3,887	4,116	4,172
TOTAL EQUITY & LIABILITIES	6,992	7,380	7,606	8,019	8,388	8,884	9,469
CHECK — must be nil	-	-	-	-	-	-	-

Indirect method | EUR '000 | Every line is derived from the P&L, balance sheet and schedules

EUR '000	FY2024A	FY2025A	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Operating activities							
Profit before tax		424	438	658	898	1,097	1,295
Depreciation & amortisation		238	243	255	266	277	289
Net finance costs		88	111	94	73	53	32
Operating profit before working capital		750	792	1,006	1,237	1,428	1,616
(Increase) / decrease in inventory		(125)	(169)	(111)	(94)	(108)	(89)
(Increase) / decrease in trade receivables		(200)	(149)	(139)	(154)	(136)	(154)
(Increase) / decrease in other receivables		(30)	(38)	(32)	(32)	(31)	(29)
Increase / (decrease) in trade payables		303	217	160	145	162	144
Increase / (decrease) in accruals		75	79	57	55	54	51
Working capital movement		23	(59)	(65)	(80)	(58)	(78)
Cash generated from operations		773	733	941	1,157	1,370	1,538
Interest paid, net of interest received		(88)	(111)	(94)	(73)	(53)	(32)
Tax paid		(59)	(151)	(102)	(142)	(178)	(212)
Net cash from operating activities		626	471	745	942	1,138	1,294
Investing activities							
Capital expenditure		(286)	(301)	(308)	(323)	(334)	(358)
Net cash used in investing activities		(286)	(301)	(308)	(323)	(334)	(358)
Financing activities							
Repayment of bank borrowings		(300)	(300)	(300)	(300)	(300)	(300)
Principal element of lease payments		(55)	(58)	(60)	(63)	(67)	(70)
Dividends paid		-	-	-	(224)	(273)	(323)
Net cash used in financing activities		(355)	(358)	(360)	(587)	(640)	(692)
Net movement in cash		(15)	(188)	77	32	164	244
Opening cash		630	615	427	504	536	700
Closing cash		615	427	504	536	700	944
Free cash flow before financing		340	170	437	619	804	936
							Operating cash less capital expenditure

Kestrel Nutrition Kft. — Supporting schedules

Fixed assets, leases, debt, working capital, tax and equity roll-forwards

EUR '000	FY2024A	FY2025A	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
FIXED ASSETS — property, plant & equipment and intangibles							
Opening net book value		1,720	1,820	1,930	2,035	2,144	2,254
Capital expenditure		286	301	308	323	334	358
Depreciation & amortisation charge		(186)	(191)	(203)	(214)	(225)	(237)
Closing net book value		1,820	1,930	2,035	2,144	2,254	2,375
RIGHT-OF-USE ASSETS							
Opening balance		572	520	468	416	364	312
Amortisation		(52)	(52)	(52)	(52)	(52)	(52)
Closing balance		520	468	416	364	312	260
BANK DEBT							
Opening balance		1,950	1,650	1,350	1,050	750	450
Repayment		(300)	(300)	(300)	(300)	(300)	(300)
Closing balance		1,650	1,350	1,050	750	450	150
of which current portion	300	300	300	300	300	300	150
of which non-current		1,350	1,050	750	450	150	-
Interest charge		(59)	(91)	(74)	(58)	(41)	(25)
LEASE LIABILITIES							
Opening balance		585	530	473	412	349	282
Interest accretion		29	27	24	21	17	14
Lease payments		(84)	(84)	(84)	(84)	(84)	(84)
Closing balance		530	473	412	349	282	212
principal element of payments		55	58	60	63	67	70
of which current portion	140	145	60	63	67	70	73
of which non-current		385	412	349	282	212	139
WORKING CAPITAL							
Trade receivables	2,010	2,210	2,359	2,498	2,652	2,787	2,942
Inventory	1,720	1,845	2,014	2,125	2,220	2,327	2,416
Other receivables & prepayments	255	285	323	355	387	418	447
Trade payables	1,845	2,148	2,365	2,526	2,671	2,833	2,977
Accruals & other payables	545	620	699	756	812	866	917
TAX							
Opening tax payable		82	95	19	28	38	47
Charge for the year		72	74	112	153	187	220
Tax paid		(59)	(151)	(102)	(142)	(178)	(212)
Closing tax payable		95	19	28	38	47	55
EQUITY							
Opening retained earnings		1,390	1,742	2,106	2,652	3,174	3,811
Profit for the year		352	364	546	746	911	1,075
Dividends paid		-	-	-	(224)	(273)	(323)
Closing retained earnings		1,742	2,106	2,652	3,174	3,811	4,564

Payment less the interest accretion